Latest articles
No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Financial Histories
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
Overview
BPMCDay performance
| BPMC | |
|---|---|
| Price | 68.45 |
| Change Pct | 2.15 |
| Change Abs | 1.44 |
| Market Cap | 4.2 billion |
| Eps | -9.20 |
| Pe Ratio | -7.44 |
| Outstanding Shares | 60.8 million |
| Volume | 284751 |
| Avg Volume | 636436 |
| Industry | Biotechnology |
| Sector Name | Health Care |
| Country Short Name | US |
| Announcement Earnings | 2024-02-14 13:30:00+00:00 |
Dividends
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Risk Profiles
Please sign up and become a member to view all risk profiles.
Peers
MDGL
KRYS
KRTX
3 Login now
4 Login now
Focus
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
BPMC
Company descriptions
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.